Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

The application is for a novel psychedelic-based combination, of Clearmind’s MEAI and SciSparc’s Cannamide Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated…


The product has been added to your cart.

Continue shopping View Cart